39369616|t|Epigenetic age acceleration is associated with occupational exposures, sex, and survival in amyotrophic lateral sclerosis.
39369616|a|BACKGROUND: Amyotrophic lateral sclerosis (ALS) is linked to ageing and genetic and environmental risk factors, yet underlying mechanisms are incompletely understood. We aimed to evaluate epigenetic age acceleration (EAA), i.e., DNA methylation (DNAm) age acceleration, and its association with ALS case status and survival. METHODS: In this study, we included 428 ALS and 288 control samples collected between 2011 and 2021. We calculated EAA using the GrimAge residual method from ALS and control blood samples and grouped participants with ALS into three ageing groups (fast, normal, slow). We associated EAA with ALS case status and survival, stratified by sex, and correlated it with environmental and biological factors through occupational exposure assessments, immune cell proportions, and transcriptome changes. FINDINGS: Participants with ALS had higher average EAA by 1.80 +- 0.30 years (p < 0.0001) versus controls. Participants with ALS in the fast ageing group had a hazard ratio of 1.52 (95% confidence interval 1.16-2.00, p = 0.0028) referenced to the normal ageing group. In males, this hazard ratio was 1.55 (95% confidence interval 1.11-2.17, p = 0.010), and EAA was positively correlated with high-risk occupational exposures including particulate matter (adj.p < 0.0001) and metals (adj.p = 0.0087). Also, in male participants with ALS, EAA was positively correlated with neutrophil proportions and was negatively correlated with CD4+ T cell proportions. Pathways dysregulated in participants with ALS with fast ageing included spliceosome, nucleocytoplasmic transport, axon guidance, and interferons. INTERPRETATION: EAA was associated with ALS case status and, at least in males, with shorter survival after diagnosis. The effect of EAA on ALS was partially explained by occupational exposures and immune cell proportions in a sex-dependent manner. These findings highlight the complex interactions of ageing and exposures in ALS. FUNDING: NIH, CDC/National ALS Registry, ALS Association, Dr. Randall Whitcomb Fund for ALS Genetics, Peter Clark Fund for ALS Research, Sinai Medical Staff Foundation, Scott L. Pranger ALS Clinic Fund, NeuroNetwork Therapeutic Discovery Fund, NeuroNetwork for Emerging Therapies.
39369616	92	121	amyotrophic lateral sclerosis	Disease	MESH:D000690
39369616	135	164	Amyotrophic lateral sclerosis	Disease	MESH:D000690
39369616	166	169	ALS	Disease	MESH:D000690
39369616	418	421	ALS	Disease	MESH:D000690
39369616	488	491	ALS	Disease	MESH:D000690
39369616	606	609	ALS	Disease	MESH:D000690
39369616	666	669	ALS	Disease	MESH:D000690
39369616	740	743	ALS	Disease	MESH:D000690
39369616	972	975	ALS	Disease	MESH:D000690
39369616	1069	1072	ALS	Disease	MESH:D000690
39369616	1476	1479	ALS	Disease	MESH:D000690
39369616	1574	1577	CD4	Gene	920
39369616	1642	1645	ALS	Disease	MESH:D000690
39369616	1786	1789	ALS	Disease	MESH:D000690
39369616	1886	1889	ALS	Disease	MESH:D000690
39369616	2072	2075	ALS	Disease	MESH:D000690
39369616	2104	2107	ALS	Disease	MESH:D000690
39369616	2118	2121	ALS	Disease	MESH:D000690
39369616	2165	2168	ALS	Disease	MESH:D000690
39369616	2200	2203	ALS	Disease	MESH:D000690
39369616	2263	2266	ALS	Disease	MESH:D000690
39369616	Association	MESH:D000690	920

